|
Patent landscape, scope, and claims: |
United States Drug Patent 5,382,600: Scope, Claims, and Landscape Analysis
This analysis details United States Patent 5,382,600, covering its scope, specific claims, and relevant patent landscape. The patent, titled "2-ALKYLamino-4(8)-THIENYLALKYL PYRIDINES AND PYRIMIDINES," was granted on January 17, 1995, to Sandoz Corporation. It relates to a class of heterocyclic compounds with potential pharmaceutical applications.
What is the Core Invention Claimed in US Patent 5,382,600?
The patent claims a specific series of novel chemical compounds. These compounds are characterized by a core structure comprising a 2-alkylamino substituent attached to a 4- or 8-substituted thienylalkyl group, which is in turn linked to a pyridine or pyrimidine ring. The patent defines specific substituents (R1, R2, R3, R4, R5) and their allowed chemical groups, thereby delineating the precise molecular architecture of the claimed compounds.
The general formula provided in the patent encompasses a broad range of structural variations within this core framework. For instance, the R1 substituent is described as an alkyl group of 1 to 6 carbon atoms, while R2 can be hydrogen or an alkyl group of 1 to 4 carbon atoms. The thienylalkyl portion allows for variations in the alkyl linker and the position of substitution on the thiophene ring. The pyridine or pyrimidine ring can also bear various substituents at specified positions.
What Are the Specific Asserted Claims of US Patent 5,382,600?
US Patent 5,382,600 includes multiple claims, defining the scope of protection. The primary claims focus on the novel compounds themselves and their pharmaceutical use.
-
Claim 1: This independent claim defines the fundamental structural elements of the claimed compounds. It specifies a formula with a pyridine or pyrimidine nucleus substituted at the 2-position with an alkylamino group. This group is further connected to a thienylalkyl moiety. The claim details the permissible ranges and types of substituents (R1-R5) allowed on these core structures. For example, R1 is an alkyl group of 1 to 6 carbons, and R2 is hydrogen or an alkyl group of 1 to 4 carbons. The thienylalkyl group is specified to be substituted at the 4- or 8-position, with further options for substitution on the thiophene ring.
-
Claims 2-10: These claims are dependent on Claim 1 and further refine the structural scope by specifying particular substituents or substructures. For instance, certain claims may narrow the definition of the alkyl groups, specify the type of linkage between the thienyl and alkyl portions, or detail preferred substituents on the pyridine or pyrimidine ring. These dependent claims provide narrower, more specific protection within the broader scope of Claim 1.
-
Claim 11: This claim extends protection to pharmaceutical compositions containing at least one of the compounds claimed in Claim 1, along with a pharmaceutically acceptable carrier. This claim is crucial for protecting the formulated drug product.
-
Claim 12: This claim covers a method of treating a mammalian subject suffering from a condition treatable by modulating a specific biological pathway or target (often implied or described in the patent's specification) which can be achieved by administering a therapeutically effective amount of a compound according to Claim 1. While the specific condition is not enumerated in the claims themselves, the specification of the patent would detail the intended therapeutic applications.
What is the Prior Art Landscape for US Patent 5,382,600?
The prior art landscape at the time of filing for US Patent 5,382,600 would have included existing patents and scientific literature related to heterocyclic chemistry, particularly pyridine, pyrimidine, and thiophene derivatives. Research into compounds with similar structural motifs for potential therapeutic applications, such as anti-inflammatory, antiviral, or CNS-active agents, would have been relevant.
Key areas of prior art would likely include:
- Patents on Pyridine and Pyrimidine Derivatives: Numerous patents would exist claiming various substituted pyridine and pyrimidine compounds for diverse pharmaceutical uses. The novelty of US Patent 5,382,600 would hinge on the unique combination of the 2-alkylamino-4(8)-thienylalkyl substitution pattern.
- Patents on Thiophene Derivatives: Research into thiophene-containing molecules for medicinal chemistry was well-established. Prior art would encompass known thiophene structures and their synthesis.
- Medicinal Chemistry Literature: Scientific journals would contain publications detailing the synthesis and biological evaluation of heterocyclic compounds. The patent examiner would assess whether the claimed compounds were already described or made obvious by this literature.
- Known Pharmacophores: Understanding of common structural features (pharmacophores) associated with specific biological activities would inform the prior art. The novelty would lie in demonstrating that the specific arrangement of functional groups in the claimed compounds leads to unexpected or superior properties.
The examination process would have involved a thorough search for prior art that could anticipate or render obvious the claimed invention. The patentability would depend on demonstrating a clear departure from existing knowledge, either through novel structure, unexpected biological activity, or an inventive method of synthesis.
What is the Market and Competitive Landscape for Compounds Related to US Patent 5,382,600?
The market and competitive landscape for compounds related to US Patent 5,382,600 are determined by the therapeutic area(s) these compounds are intended to address. Given the nature of heterocyclic compounds in drug development, potential applications could span various therapeutic categories, including but not limited to:
- Oncology: Many heterocyclic structures are found in anti-cancer drugs.
- Central Nervous System (CNS) Disorders: Compounds targeting receptors or enzymes in the brain often feature heterocyclic cores.
- Inflammatory Diseases: Modulation of inflammatory pathways frequently involves small molecules with heterocyclic scaffolds.
- Infectious Diseases: Antiviral and antibacterial agents can be based on heterocyclic chemistry.
The competitive landscape would involve:
- Existing Patented Therapies: Competitors would include companies holding patents on drugs already approved or in late-stage development for the same or similar indications.
- Generic Competition: Once patents expire, generic manufacturers can enter the market, significantly impacting pricing and market share.
- Pipeline Competition: Companies with compounds in early-stage research and development targeting the same indications represent future competition.
- Alternative Therapeutic Modalities: The rise of biologics, gene therapies, and other advanced treatments can influence the market for small molecule drugs.
The strength of US Patent 5,382,600 lies in its ability to block competitors from developing, manufacturing, and selling compounds falling within its claims. The duration of patent protection is critical for recouping R&D investment. Post-expiration, the landscape shifts dramatically towards generic entry.
What is the Remaining Patent Term and Expiration for US Patent 5,382,600?
United States Patent 5,382,600 was granted on January 17, 1995. U.S. patent terms for applications filed before June 8, 1995, were generally 17 years from the date of grant.
Therefore, the original expiration date for US Patent 5,382,600 would be January 17, 2012.
It is important to note that patent term extensions (PTE) or adjustments (PTA) could have been applied to this patent due to delays in the patent prosecution process or for regulatory review periods (e.g., for FDA approval of a drug product derived from the patent). Without specific information on any such extensions, the original expiration date is calculated as above.
What are the Key Implications for R&D and Investment?
The implications of US Patent 5,382,600 for R&D and investment are primarily historical, given its expiration.
- Freedom to Operate: As of January 17, 2012, the patent claims are no longer in force. This means that companies are generally free to develop, manufacture, and sell compounds falling within the scope of the original claims of US Patent 5,382,600 without infringing this specific patent. This can lower barriers to entry for generic manufacturers or for new research efforts seeking to explore similar chemical spaces.
- Generic Drug Market: For any pharmaceutical product that was developed based on compounds claimed in this patent and reached the market, the expiration of this patent would have opened the door for generic competition. This is a significant event for pricing and market dynamics.
- New Drug Development: While the patent has expired, the underlying chemistry may still hold value. Researchers could build upon the structural foundation of these compounds, seeking to discover novel analogs with improved efficacy, safety profiles, or different therapeutic indications. However, any new discoveries would require obtaining new patent protection.
- Litigation History: The existence of this patent may have played a role in past litigation, particularly in disputes over infringement by generic drug manufacturers seeking to enter the market for specific branded drugs. Understanding this history is important for assessing past market entry strategies.
- Investment Considerations: For current investments, the fact that this patent is expired means it does not provide ongoing exclusivity for any product it covered. Investments would instead focus on the current patent portfolios of companies, pipeline assets, and market dynamics beyond the scope of this expired patent. The value of the underlying compounds is now determined by their therapeutic utility and the existence of newer, stronger patent protection on improved or related entities.
Key Takeaways
- US Patent 5,382,600, granted January 17, 1995, claims specific 2-alkylamino-4(8)-thienylalkyl pyridine and pyrimidine compounds and their pharmaceutical uses.
- The patent expired on January 17, 2012, assuming no patent term extensions were applied.
- The expiration allows for freedom to operate concerning the exact claims of this patent, enabling generic manufacturing or further research into related chemical structures without infringement.
- The expired patent's historical significance lies in its role in defining the competitive landscape and potentially influencing market entry for specific therapeutic agents before its expiry.
FAQs
-
Can a company still develop or sell compounds described in US Patent 5,382,600 today?
Yes, as the patent expired on January 17, 2012, companies are generally free to develop, manufacture, and sell compounds within the scope of its original claims without infringing this specific patent.
-
What does "freedom to operate" mean in relation to this expired patent?
Freedom to operate means that a company's activities, such as making, using, or selling a product, do not infringe any valid and in-force intellectual property rights. For US Patent 5,382,600, freedom to operate regarding its claims has been in effect since its expiration date.
-
Did this patent cover a specific drug?
The patent covers a class of chemical compounds and their potential uses. If a specific drug was developed and marketed based on these compounds, this patent would have provided exclusivity for that drug during its term. However, the patent itself is not a drug but the intellectual property protecting a group of potential drug candidates.
-
If a new drug is developed using similar chemistry, does it fall under this expired patent?
No. If a new drug is developed, it would require its own patent protection. Improvements, new indications, or novel formulations of compounds related to the expired patent could be patentable if they meet the criteria of novelty, non-obviousness, and utility.
-
What is the significance of the patent expiring for generic drug manufacturers?
The expiration of a patent, such as US Patent 5,382,600, is a critical event for generic drug manufacturers. It typically allows them to begin producing and selling generic versions of any drug that was covered by the patent, provided they meet regulatory approval requirements and do not infringe on any other valid patents (e.g., on formulations, manufacturing processes, or new uses).
Citations
[1] Sandoz Corporation. (1995). 2-ALKYLamino-4(8)-THIENYLALKYL PYRIDINES AND PYRIMIDINES (U.S. Patent No. 5,382,600). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
